NCT05638815 (EASE-PD) is a clinical trial in Parkinson's Disease, sponsored by SciNeuro.

Who is sponsoring NCT05638815?

NCT05638815 is sponsored by SciNeuro.

What condition does NCT05638815 study?

NCT05638815 studies Parkinson's Disease, Multiple System Atrophy.

Is NCT05638815 still recruiting?

NCT05638815 is currently completed. Last updated 22 November 2023.

Last reviewed 2023-11-22 · How we verify

NCT05638815: EASE-PD

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

An Observational Study of Parkinson's Disease and Other Synucleinopathies (EASE-PD)

Completed Last updated 22 November 2023

What this trial tests

trial in Parkinson's Disease in 89 participants. Completed in 10 July 2023.

Timeline

23 November 2021

Primary endpoint
10 July 2023

10 July 2023

Quick facts

Lead sponsor	SciNeuro
Status	Completed
Study type	OBSERVATIONAL
Enrollment	89
Start date	23 November 2021
Primary completion	10 July 2023
Estimated completion	10 July 2023
Sites	4 locations across China

Conditions studied

Parkinson's Disease — all drugs for Parkinson's Disease →
Multiple System Atrophy — all drugs for Multiple System Atrophy →

Sponsor

SciNeuro — full company profile →

Who can join

40 and older, any sex, with Parkinson's Disease or Multiple System Atrophy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study is a multi-center, observational study to evaluate the feasibility of α-synuclein-related biomarkers and imaging data in the disease diagnosis and prognosis evaluation in Synucleinopathies and healthy subjects.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Multiple system atrophy: an update and emerging directions of biomarkers and clinical trials.
Liu M, Wang Z, Shang H. · · 2024 · cited 19× · PMID 38483626 · DOI 10.1007/s00415-024-12269-5

Verify or expand the search:

Other recruiting trials for Parkinson's Disease

Currently open trials in the same condition.

NCT07371338 — Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients · Phase 1 · recruiting
NCT07330258 — A US Study That Observes How Parkinson's Disease Changes Over Time in Patients Who Still Have Movement Symptoms Despite · recruiting
NCT07384429 — Effects of Lemborexant on Motor-sleep Comorbidity in Parkinson's Disease · Phase 4 · recruiting
NCT07384442 — Effects of Targeted Temporal Interference Stimulation of Cerebellar Nuclei on Tremor and Gait Disturbance in Parkinson's · NA · recruiting
NCT06562569 — Non-invasive VNS for PD Gait · NA · recruiting

Other SciNeuro trials

Trials by the same sponsor.

NCT05792163 — A First Time in Human Study of SNP318 as a Treatment for Neurodegenerative Diseases Including Alzheimer's Disease · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05638815 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by SciNeuro
Last refreshed: 22 November 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05638815.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing